Elexacaftor, tezacaftor, and ivacaftor and Itraconazole interaction

Elexacaftor, tezacaftor, and ivacaftor and Itraconazole: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Itraconazole (Tolsura) label · effective 2025-04-23

Major

Lumacaftor/Ivacaftor Not recommended 2 weeks before, during, and 2 weeks after TOLSURA treatment.

Drug interactionsnames Elexacaftor, tezacaftor, and ivacaftorView label on DailyMed
Major

Miscellaneous Drugs and Other Substances Lumacaftor/Ivacaftor Not recommended 2 weeks before, during, and 2 weeks after TOLSURA treatment.

Drug interactionsnames Elexacaftor, tezacaftor, and ivacaftorView label on DailyMed
Moderate

Alitretinoin (oral) Cabergoline Cannabinoids Cinacalcet Ivacaftor Monitor for adverse reactions.

Drug interactionsnames Elexacaftor, tezacaftor, and ivacaftorView label on DailyMed

From the Elexacaftor, tezacaftor, and ivacaftor (Trikafta) label · effective 2026-06-22

Moderate

When used concomitantly with itraconazole and ketoconazole, ivacaftor AUC increased by 15.6-fold and 8.5-fold, respectively [see Clinical Pharmacology (12.3) ] .

Drug interactionsnames ItraconazoleView label on DailyMed
Moderate

Concomitant Use with CYP3A Inhibitors Exposure to elexacaftor, tezacaftor and ivacaftor are increased when used concomitantly with strong or moderate CYP3A inhibitors.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Therefore, the dose of TRIKAFTA should be reduced when used concomitantly with moderate or strong CYP3A inhibitors [see Dosage and Administration (2.4) , Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] .

Warnings and precautionsby drug classView label on DailyMed
Moderate

Strong or moderate CYP3A inhibitors: Reduce TRIKAFTA dosage when used concomitantly.

Drug interactionsby drug classView label on DailyMed
Moderate

John's wort ( Hypericum perforatum ) Strong or Moderate CYP3A Inhibitors The dosage of TRIKAFTA should be reduced when used concomitantly with strong CYP3A inhibitors [see Dosage and Administration (2.4) and Warnings and Precautions (5.6) ] .

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.